SCHEMBL5482053

SCHEMBL5482053

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3c2ccc(Cl)c3C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
CNR1 P21554 1/20 0.41
HTT P42858 1/20 0.41
GPR35 Q9HC97 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
LMNA P02545 2/20 0.40
ALDH1A1 P00352 6/20 0.35
USP2 O75604 4/20 0.35
CES1 P23141 1/20 0.35
POLB P06746 2/20 0.34
PKM P14618 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GLA P06280 2/20 0.33
ELANE P08246 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
ERG P11308 1/20 0.33
ETV1 P50549 1/20 0.33
FLI1 Q01543 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5480076 0.86 MAPT (0.43) MAPTLMNAALDH1A1CES1POLB
SCHEMBL5481638 0.84 MAPT (0.40) MAPTCNR1HTTGPR35GPR55
SCHEMBL5478229 0.82 MAPT (0.54) MAPTCNR1HTTGPR35GPR55
SCHEMBL5482836 0.82 MAPT (0.50) MAPTCNR1HTTGPR35GPR55
SCHEMBL5485571 0.81 CNR1 (0.52) MAPTCNR1HTTGPR35GPR55
SCHEMBL5474643 0.81 CNR1 (0.61) MAPTCNR1HTTGPR35GPR55
SCHEMBL5478235 0.81 HTT (0.46) MAPTCNR1HTTGPR35GPR55
SCHEMBL5482094 0.81 MAPT (0.49) MAPTCNR1HTTGPR35GPR55
SCHEMBL5479020 0.81 MAPT (0.48) MAPTCNR1HTTGPR35GPR55
SCHEMBL5478939 0.80 SMN1; SMN2 (0.56) MAPTCNR1HTTGPR35GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885CNR1 973/4885HTT 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.